Reassessment of statins to retard the progression of aortic stenosis

Current Cardiology Reports

Volumn 9, Issue 2, 2007, Pages 99-104

  Rajamannan, Nalini M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E2; ATORVASTATIN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NOTCH1 RECEPTOR; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TRANDOLAPRIL; VITAMIN D RECEPTOR;

AORTA VALVE STENOSIS; ATHEROSCLEROSIS; CALCIFICATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORRELATION ANALYSIS; EPIDEMIOLOGICAL DATA; EUROPE; GENETIC POLYMORPHISM; HEART VALVE REPLACEMENT; HUMAN; META ANALYSIS; OUTCOMES RESEARCH; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION; UNITED STATES; VALVULAR HEART DISEASE;

ANIMALS; AORTIC VALVE STENOSIS; ATHEROSCLEROSIS; CALCINOSIS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 34247573373     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02938335     Document Type: Review

References (42)

1. Bonow RO, Carabello BA, Kanu C, et al.: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006, 114:e84-e231.
2. Whyte HM: The relative importance of the major risk factors in atherosclerotic and other diseases. Aust N Z J Med 1976, 6:387-393.
3. Stewart BF, Siscovick D, Lind BK, et al.: Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997, 29:630-634.
4. Otto CM, Lind BK, Kitzman DW, et al.: Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly [comment]. N Engl J Med 1999, 341:142-147.
5. Aronow WS, Ahn C, Kronzon I, Goldman ME: Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001, 88:693-695.
6. Boon A, Cheriex E, Lodder J, Kessels F: Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart 1997, 78:472-474.
7. Chan KL, Ghani M, Woodend K, Burwash IG: Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. Am J Cardiol 2001, 88:690-693.
8. Chui MC, Newby DE, Panarelli M, et al.: Association between calcific aortic stenosis and hypercholestcrolemia: is there a need for a randomized controlled trial of cholesterol-lowering therapy? Clin Cardiol 2001, 24:52-55.
9. Pohle K, Maffert R, Ropers D, et al.: Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001, 104:1927-1932.
10. Palta S, Pai AM, Gill KS, Pai RG: New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 2000, 101:2497-2502.
11. Galante A, Pietroiusti A, Vellini, M, et al.: C-reactive protein is increase in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001, 38:1078-1081.
12. O'Brien KD, Reichenbach DD, Marcovina SM, et al.: Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996, 16:523-532.
13. Olsson M, Thyberg J, Nilsson J: Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999, 19:1218-1222.
14. Mohler ER 3rd, Adam LP, McClelland P, et al.: Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol 1997, 17:547-552.
15. O'Brien KD, Kuusisto J, Reichenbach DD, et al.: Osteopontin is expressed in human aortic valvular lesions. Circulation 1995, 92:2163-2168.
16. Mohler ER 3rd, Gannon F, Reynolds C, et al.: Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522-1528.
17. Rajamannan NM, Subramaniam M, Rickard D, et al.: Human aortic valve calcification is associated with an ostcoblast phenotype. Circulation 2003, 107:2181-2184.
18. Parhami F, Morrow AD, Balucan J, et al.: Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997, 17:680-687.
19. Demer LL: Cholesterol in vascular and valvular calcification. Circulation 2001, 104:1881-1883.
20. Rosenhek R, Binder T, Porenta G, et al.: Predictors of outcome in severe asymptomatic aortic stenosis. N Engl J Med 2000, 343:611-617.
21. Garg V, Muth AN, Ransom JF, et al.: Mutations in NOTCH1 cause aortic valve disease. Nature 2005, 437:270-274.
22. Ortlepp JR, Hoffmann R, Ohme F, et al.: The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 2001, 85:635-638.
23. Avakian SD, Annicchino-Bizzacchi JM, Grinberg M. et al.: Apolipoproteins AI, B, and E polymorphisms in severe aortic valve stenosis. Clin Genet 2001, 60:381-384.
24. O'Brien KD, Kuusisto J, Reichenbach DD, et al.: Osteopontin is expressed in human aortic valvular lesions [comment]. Circulation 1995, 92:2163-2168.
25. Rajamannan NM, Sangiorgi G, Springett M, et al.: Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis 2001, 10:371-374.
26. Rajamarman NM, Subramaniam M, Springett M, et al.: Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002, 105:2260-2265.
27. Makkena B, Salti H, Subramaniam M, et al.: Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve. J Am Coll Cardiol 2005, 45:631-633.
28. Weiss RM, Ohashi M, Miller JD, et al.: Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 2006, 114:2065-2069.
29. Gong Y, Slee RB, Fukai N, et al.: for the Osteoporosis-Pseudoglioma Syndrome Collaborative Group: LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001, 107:513-523.
30. Little RD, Carulli JP, Del Mastro RG, et al.: A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002, 70:11-19.
31. Aliev G, Burnstock G: Watanabe rabbits with heritable hypercholesterolaemia: a model of atherosclerosis. Histol Histopathol 1998, 13:797-817.
32. Hoeg JM, Feuerstein IM, Tucker EE: Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb 1994, 14:1066-1074.
33. Novaro GM, Tiong IY, Pearce GL, et al.: Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stcnosis. Circulation 2001, 104:2205-2209.
34. Rosenhek R, Rader F, Loho N, et al.: Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004, 110:1291-1295.
35. Bellamy MF, Pellikka PA, Klarich KW, et al.: Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community [comment]. J Am Coll Cardiol 2002, 40:1723-1730.
36. O'Brien KD, Zhao XQ, Shavelle DM, et al.: Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med 2004, 52:185-191.
37. O'Brien KD, Shavelle DM, Caulfield MT, et al.: Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002, 106:2224-2230.
38. Antonini-Canterin F, Corrado G, Faggiano P, et al.: A medical therapy for aortic valve sclerosis and aortic valve stenosis? Rationale of the ASSIST study (Asymptomatic aortic Sclerosis/Stenosis: Influence of STatins): a large, observational, prospective, multicenter study of the Italian Society of Cardiovascular Echography. J Cardiovasc Med (Hagerstown) 2006, 7:464-469.
39. O'Brien KD, Probstfield JL, Caulfield MT, et al.: Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005, 165:858-862.
40. Cowell SJ, Newby DE, Prescott RJ, et al.: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005, 352:2389-2397.
41. Rossebo A, Pedersen T, Skjaerpe T, et al.: Design of the Simvastatin and Ezetimide in Aortic Stenosis (SEAS) study. Atherosclerosis 2003, 170(Suppl 4):abstract 253.
42. Moura LM, Ramos SF, Zamorano JI, et al.: Rosuvastatin Affecting Aortic Valve Endothelium (RAAVE) to slow progression of aortic stenosis. Circulation 2006, 114:11-175.